Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Liver and COVID-19 - A Review and Clinical Approach

Author(s): David L. Fisher and Stephen Malnick*

Volume 3, Issue 1, 2022

Published on: 05 October, 2021

Article ID: e221221197017 Pages: 7

DOI: 10.2174/2666796702666211005142343

Price: $65

Abstract

Liver enzyme abnormalities occur frequently in patients diagnosed with Coronavirus disease 2019 (COVID-19). It has been suggested that patients with severe acute liver injury are more likely to be admitted to intensive care, require intubation or renal replacement therapy and their mortality rate is higher than patients without severe acute liver injury. This review article explores the possible aetiologies of liver dysfunction seen in patients with COVID-19 and also the effect of COVID-19 on patients with pre-existing liver disease. Finally, we suggest clinical approaches to treating a patient with liver enzyme disturbance and COVID-19 and also caring for patients who require liver transplantation in the COVID-19 era.

Keywords: COVID-19, liver disease, liver transplant, hepatitis, MAFLD, coronavirus disease 2019.

Graphical Abstract

[1]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[2]
Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int 2021; 41(1): 20-32.
[http://dx.doi.org/10.1111/liv.14730] [PMID: 33190346]
[3]
Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol 2021; 74(1): 168-84.
[http://dx.doi.org/10.1016/j.jhep.2020.09.031] [PMID: 33038433]
[4]
Wang Q, Zhao H, Liu LG, et al. Pattern of liver injury in adult patients with COVID-19: A retrospective analysis of 105 patients. Mil Med Res 2020; 7(1): 28.
[http://dx.doi.org/10.1186/s40779-020-00256-6] [PMID: 32507110]
[5]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[6]
Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: Prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology 2020; 72(3): 807-17.
[http://dx.doi.org/10.1002/hep.31404] [PMID: 32473607]
[7]
Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73(3): 566-74.
[http://dx.doi.org/10.1016/j.jhep.2020.04.006] [PMID: 32298767]
[8]
Anastasiou OE, Korth J, Herbstreit F, Witzke O, Lange CM. Mild vs severe liver injury in SARS-CoV-2 infection. Dig Dis 2020; 39(1): 52-7.
[http://dx.doi.org/10.1159/000510758] [PMID: 32777784]
[9]
Lopez-Mendez I, Aquino-Matus J, Gall SMB, et al. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19). Ann Hepatol 2021; 20: 100271.
[http://dx.doi.org/10.1016/j.aohep.2020.09.015] [PMID: 33099028]
[10]
Lei F, Liu Y-M, Zhou F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020; 72(2): 389-98.
[http://dx.doi.org/10.1002/hep.31301] [PMID: 32359177]
[11]
Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: A retrospective observational cohort study of 1,827 patients in a major U.S. hospital network. Hepatology 2020; 72(4): 1169-76.
[http://dx.doi.org/10.1002/hep.31487] [PMID: 32725890]
[12]
Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: A systematic review and meta-analysis. Hepatol Int 2020; 14(5): 612-20.
[http://dx.doi.org/10.1007/s12072-020-10078-2] [PMID: 32725453]
[13]
Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020; 18(7): 1561-6.
[http://dx.doi.org/10.1016/j.cgh.2020.04.002] [PMID: 32283325]
[14]
Bangash MN, Patel J, Parekh D. COVID-19 and the liver: Little cause for concern. Lancet Gastroenterol Hepatol 2020; 5(6): 529-30.
[http://dx.doi.org/10.1016/S2468-1253(20)30084-4] [PMID: 32203680]
[15]
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20): 2052-9.
[http://dx.doi.org/10.1001/jama.2020.6775] [PMID: 32320003]
[16]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[17]
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020; 40(5): 998-1004.
[http://dx.doi.org/10.1111/liv.14435] [PMID: 32170806]
[18]
Bernal-Monterde V, Casas-Deza D, Letona-Giménez L, et al. SARS-CoV-2 infection induces a dual response in liver function tests: Association with mortality during hospitalization. Biomedicines 2020; 8(9): 328.
[http://dx.doi.org/10.3390/biomedicines8090328] [PMID: 32899640]
[19]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[20]
Chai X, Hu L, Zhang Y, Han W. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-NCoV infection. BioRxiv 2020. (pre-print).
[http://dx.doi.org/10.1101/2020.02.03.931766]
[21]
Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol 2020; 16(7): e9610.
[http://dx.doi.org/10.15252/msb.20209610] [PMID: 32715618]
[22]
Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal liver function tests in patients with COVID-19: Relevance and potential pathogenesis. Hepatology 2020; 72(5): 1864-72.
[http://dx.doi.org/10.1002/hep.31480] [PMID: 32702162]
[23]
Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of Coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis 2020; 71(15): 756-61.
[http://dx.doi.org/10.1093/cid/ciaa247] [PMID: 32161968]
[24]
Elsoukkary SS, Mostyka M, Dillard A, et al. Autopsy findings in 32 patients with COVID-19: A single-institution experience. Pathobiology 2020; 88(1): 1-13.
[http://dx.doi.org/10.1159/000511325] [PMID: 32942274]
[25]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[26]
Anirvan P, Narain S, Hajizadeh N, Aloor FZ, Singh SP, Satapathy SK. Cytokine-Induced liver injury in coronavirus disease-2019 (COVID-19): Untangling the knots. Eur J Gastroenterol Hepatol 2021. Publish Ahead of Print .
[http://dx.doi.org/10.1097/MEG.0000000000002034] [PMID: 33405427]
[27]
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020; 383(19): 1827-37.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]
[28]
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-76.
[http://dx.doi.org/10.3748/wjg.v23.i47.8263] [PMID: 29307986]
[29]
Farrell GC, Wong VW-S, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013; 10(5): 307-18.
[http://dx.doi.org/10.1038/nrgastro.2013.34] [PMID: 23458891]
[30]
Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020; 73(2): 451-3.
[http://dx.doi.org/10.1016/j.jhep.2020.03.044] [PMID: 32278005]
[31]
Mushtaq K, Khan MU, Iqbal F, et al. NAFLD is a predictor of liver injury in covid-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues. J Hepatol 2020; 74(2): 482-4.
[http://dx.doi.org/10.1016/j.jhep.2020.09.006] [PMID: 33223215]
[32]
Zhou Y-J, Zheng KI, Wang X-B, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol 2020; 73(3): 719-21.
[http://dx.doi.org/10.1016/j.jhep.2020.04.027] [PMID: 32348790]
[33]
Assante G, Williams R, Youngson NA. Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? J Hepatol 2021; 74(2): 487-8.
[http://dx.doi.org/10.1016/j.jhep.2020.05.051] [PMID: 32574578]
[34]
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831-3.e3.
[http://dx.doi.org/10.1053/j.gastro.2020.02.055] [PMID: 32142773]
[35]
Pan L, Mu M, Yang P, et al. Clinical characteristics of covid-19 patients with digestive symptoms in hubei, china: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020; 115(5): 766-73.
[http://dx.doi.org/10.14309/ajg.0000000000000620] [PMID: 32287140]
[36]
Liu R, Zhao L, Cheng X, et al. Clinical characteristics of COVID-19 patients with Hepatitis B virus infection — a retrospective study. Liver Int 2020; 41(4): 720-30.
[http://dx.doi.org/10.1111/liv.14774] [PMID: 33351265]
[37]
Liu, R.; Zhao, L.; Cheng, X.; et al. Clinical Characteristics of COVID-19 Patients with Hepatitis B virus infection: A retrospective study. Liver Int 2020; 41(4): 720-30.
[http://dx.doi.org/10.1111/liv.14774] [PMID: 33351265]
[38]
Liu J, Wang T, Cai Q, et al. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res 2020; 50(11): 1211-21.
[http://dx.doi.org/10.1111/hepr.13553] [PMID: 32761993]
[39]
Anugwom CM, Aby ES, Debes JD. Inverse association between chronic hepatitis b infection and coronavirus disease 2019 (COVID-19): Immune exhaustion or coincidence? Clin Infect Dis 2021; 72(1): 180-2.
[PMID: 32502247]
[40]
Crawford A, Angelosanto JM, Kao C, et al. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity 2014; 40(2): 289-302.
[http://dx.doi.org/10.1016/j.immuni.2014.01.005] [PMID: 24530057]
[41]
Debes JD, de Knegt RJ, Boonstra A. The path to cancer and back: Immune modulation during hepatitis c virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals. Transplantation 2017; 101(5): 910-5.
[http://dx.doi.org/10.1097/TP.0000000000001623] [PMID: 28045877]
[42]
Mangia A, Cenderello G, Verucchi G, et al. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? World J Clin Cases 2020; 8(22): 5831-4.
[http://dx.doi.org/10.12998/wjcc.v8.i22.5831] [PMID: 33344581]
[43]
Chen YW, Yiu CB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Res 2020; 9: 129.
[http://dx.doi.org/10.12688/f1000research.22457.2] [PMID: 32194944]
[44]
Chen H, Zhang Z, Wang L, et al. First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients. Medicine (Baltimore) 2020; 99(48): e23357.
[http://dx.doi.org/10.1101/2020.03.22.20034041] [PMID: 33235105]
[45]
Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 Infection in patients with autoimmune hepatitis. J Hepatol 2021; 74(6): 1335-43.
[http://dx.doi.org/10.1016/j.jhep.2021.01.021] [PMID: 33508378]
[46]
Bajaj JS, Garcia-Tsao G, Wong F, et al. Cirrhosis is associated with high mortality and readmissions over 90 days regardless of COVID-19: A multicenter cohort. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/lt.25981
[47]
Mansoor E, Perez A, Abou-Saleh M, et al. Clinical characteristics, hospitalization, and mortality rates of coronavirus disease 2019 among liver transplant patients in the united states: A multicenter research network study. Gastroenterology 2021; 160(1): 459-462.e1.
[http://dx.doi.org/10.1053/j.gastro.2020.09.033] [PMID: 33010251]
[48]
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2021; 74(1): 148-55.
[http://dx.doi.org/10.1016/j.jhep.2020.07.040] [PMID: 32750442]
[49]
Domínguez-Gil B, Fernández-Ruiz M, Hernández D, et al. Organ donation and transplantation during the COVID-19 pandemic: A summary of the Spanish experience. Transplantation 2021; 105(1): 29-36.
[http://dx.doi.org/10.1097/TP.0000000000003528] [PMID: 33165237]

Rights & Permissions Print Cite
Article Metrics
11
3
© 2024 Bentham Science Publishers | Privacy Policy